Ephreli 2023: I-Retifanlimab-dlwr (Zynyz, Incyte Corporation) ithole ukugunyazwa okusheshayo kwa-Food and Drug Administration ukuze yelaphe iziguli ezikhulile ezinomdlavuza we-Metastatic noma ophindelelayo wendawo othuthukile we-Merkel (MCC). Ku-PODIUM-2..